165 results on '"Verburg, Frederik A"'
Search Results
2. Cardiovascular disease and radiopharmaceutical therapies– an underestimated risk?
3. Connectivity based on glucose dynamics reveals exaggerated sensorimotor network coupling on subject-level in Parkinson’s disease
4. Fiat lux: the dawn of fluorescence in molecular imaging of differentiated thyroid cancer
5. The EANM guideline on radioiodine therapy of benign thyroid disease
6. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
7. Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry
8. Current research topics in FAPI theranostics: a bibliometric analysis
9. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
10. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
11. Asinus in Tegulis—basing stark warning messages on insufficient methodology
12. The EANM practice guidelines for parathyroid imaging
13. Higher thyroid hormone levels and cancer
14. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
15. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies
16. To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “Holy Gray” in radionuclide therapy
17. Correction to: Higher thyroid hormone levels and cancer
18. Brief progress report from the intersocietal working group on differentiated thyroid cancer
19. “Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide” on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news
20. Positive [18F]fluoroethyltyrosine PET/MRI in suspected recurrence of growth hormone–producing pituitary adenoma in a paediatric patient
21. The limits of the “holy gray” in radioembolization and beyond: Beyond the “holy Gray”
22. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
23. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade
24. Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE
25. Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?
26. No time like the present: time to re-think our habits in science and continuous medical education?
27. I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth?
28. Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option
29. Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients
30. The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia
31. Use of anti-thyroid drugs in patients with hyperthyroidism: a case for shared decision-making
32. A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy
33. The “reset button” revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients
34. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT
35. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine
36. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
37. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score
38. Current research topics in FAPI theranostics: a bibliometric analysis
39. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality
40. Determinants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancer
41. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
42. 68Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging
43. [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice
44. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma
45. Thyroid nodules with indeterminate cytology: molecular imaging with 99mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma® gene expression classifier
46. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma
47. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level
48. Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up
49. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients
50. ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.